Literature DB >> 22982492

How IRBs view and make decisions about coercion and undue influence.

Robert Klitzman1.   

Abstract

INTRODUCTION: Scholars have debated how to define coercion and undue influence, but how institutional review boards (IRBs) view and make decisions about these issues in actual cases has not been explored.
METHODS: I contacted the leadership of 60 US IRBs (every fourth one in the list of the top 240 institutions by National Institutes of Health funding), and interviewed 39 IRB leaders or administrators from 34 of these institutions (response rate=55%), and 7 members.
RESULTS: IRBs wrestled with defining of 'coercion' and 'undue inducement', most notably in deciding about participant compensation. IRBs often use these terms synonymously and define undue inducement in varying ways, often wrestling with these issues, relying on 'gut feelings', and seeking compromises. Ambiguities arose, partly reflecting underlying tensions: whether subjects should 'get paid' versus 'volunteer' (ie, whether subjects should be motivated by compensation vs altruism), and whether subjects should be paid differently based on income, given possible resultant selection bias. Lack of consistent standards emerged between and even on single IRBs. Questions arose concerning certain aspects and types of studies; for example, how to view and weigh providing free care in research, whether and how recruitment flyers should mention compensation, and how to avoid coercion in paediatric, developing world, or students research.
CONCLUSIONS: These data, the first to probe qualitatively how IRBs view and approach questions about coercion, undue influence and participant compensation, and to examine how IRBs have reviewed actual cases, reveal several critical ambiguities and dilemmas, and have vital implications for future practice, education, policy and research.

Entities:  

Mesh:

Year:  2012        PMID: 22982492      PMCID: PMC3604028          DOI: 10.1136/medethics-2011-100439

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  19 in total

Review 1.  Ending concerns about undue inducement.

Authors:  Ezekiel J Emanuel
Journal:  J Law Med Ethics       Date:  2004       Impact factor: 1.718

2.  Disclosure of information to potential subjects on research recruitment web sites.

Authors:  Robert Klitzman; Ilene Albala; Joseph Siragusa; Jignasha Patel; Paul S Appelbaum
Journal:  IRB       Date:  2008 Jan-Feb

Review 3.  Uses of coercion in addiction treatment: clinical aspects.

Authors:  Maria A Sullivan; Florian Birkmayer; Beth K Boyarsky; Richard J Frances; John A Fromson; Marc Galanter; Frances R Levin; Collins Lewis; Edgar P Nace; Richard T Suchinsky; John S Tamerin; Bryan Tolliver; Joseph Westermeyer
Journal:  Am J Addict       Date:  2008 Jan-Feb

4.  Voluntariness of consent to research: a preliminary empirical investigation.

Authors:  Paul S Appelbaum; Charles W Lidz; Robert Klitzman
Journal:  IRB       Date:  2009 Nov-Dec

5.  Payment for research participation: a coercive offer?

Authors:  A Wertheimer; F G Miller
Journal:  J Med Ethics       Date:  2008-05       Impact factor: 2.903

6.  Institutional review board community members: who are they, what do they do, and whom do they represent?

Authors:  Robert Klitzman
Journal:  Acad Med       Date:  2012-07       Impact factor: 6.893

7.  Views and experiences of IRBs concerning research integrity.

Authors:  Robert Klitzman
Journal:  J Law Med Ethics       Date:  2011       Impact factor: 1.718

8.  Money, coercion, and undue inducement: attitudes about payments to research participants.

Authors:  Emily A Largent; Christine Grady; Franklin G Miller; Alan Wertheimer
Journal:  IRB       Date:  2012 Jan-Feb

9.  How local IRBs view central IRBs in the US.

Authors:  Robert Klitzman
Journal:  BMC Med Ethics       Date:  2011-06-23       Impact factor: 2.652

10.  The ethics police?: IRBs' views concerning their power.

Authors:  Robert Klitzman
Journal:  PLoS One       Date:  2011-12-13       Impact factor: 3.240

View more
  21 in total

1.  Nudges and coercion: conceptual, empirical, and normative considerations.

Authors:  Kelso Cratsley
Journal:  Monash Bioeth Rev       Date:  2015 Jun-Sep

2.  An Ethical Exploration of Barriers to Research on Controlled Drugs.

Authors:  Michael H Andreae; Evelyn Rhodes; Tyler Bourgoise; George M Carter; Robert S White; Debbie Indyk; Henry Sacks; Rosamond Rhodes
Journal:  Am J Bioeth       Date:  2016       Impact factor: 11.229

3.  The Ethical Concerns of Seeking Consent from Critically Ill, Mechanically Ventilated Patients for Research - A Matter of Possessing Capacity or Surrogate Insight.

Authors:  Avelino C Verceles; Waqas Bhatti
Journal:  Clin Ethics       Date:  2018-03-19

4.  Incentives to participate in clinical trials: practical and ethical considerations.

Authors:  Steven L Bernstein; James Feldman
Journal:  Am J Emerg Med       Date:  2015-05-29       Impact factor: 2.469

5.  Barriers to Effective Deliberation in Clinical Research Oversight.

Authors:  Danielle M Wenner
Journal:  HEC Forum       Date:  2016-09

6.  How US institutional review boards decide when researchers need to translate studies.

Authors:  Robert Klitzman
Journal:  J Med Ethics       Date:  2013-03-08       Impact factor: 2.903

7.  Bioethical Issues in Providing Financial Incentives to Research Participants.

Authors:  David B Resnik
Journal:  Medicoleg Bioeth       Date:  2015-06-24

8.  Reimagining IRB review to incorporate a clear and convincing standard of evidence.

Authors:  E Smith; E E Anderson
Journal:  Account Res       Date:  2021-02-08       Impact factor: 2.622

9.  Standards of evidence for institutional review board decision-making.

Authors:  David B Resnik
Journal:  Account Res       Date:  2020-12-08       Impact factor: 3.057

Review 10.  Overcoming Barriers to Parkinson Disease Trial Participation: Increasing Diversity and Novel Designs for Recruitment and Retention.

Authors:  Pavan A Vaswani; Thomas F Tropea; Nabila Dahodwala
Journal:  Neurotherapeutics       Date:  2020-11-04       Impact factor: 6.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.